Family Manage LLC Cuts Holdings in Gilead Sciences, Inc. $GILD

Family Manage LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 47.7% in the first quarter, Holdings Channel reports. The firm owned 29,557 shares of the biopharmaceutical company’s stock after selling 26,932 shares during the quarter. Family Manage LLC’s holdings in Gilead Sciences were worth $4,119,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Orbimed Advisors LLC bought a new stake in Gilead Sciences in the 1st quarter worth about $8,306,000. Intelligence Driven Advisers LLC boosted its holdings in shares of Gilead Sciences by 57.5% during the 1st quarter. Intelligence Driven Advisers LLC now owns 4,562 shares of the biopharmaceutical company’s stock valued at $636,000 after acquiring an additional 1,665 shares during the last quarter. Gateway Wealth Partners LLC grew its stake in shares of Gilead Sciences by 152.8% in the first quarter. Gateway Wealth Partners LLC now owns 10,298 shares of the biopharmaceutical company’s stock worth $1,435,000 after acquiring an additional 6,225 shares during the period. OMERS ADMINISTRATION Corp raised its holdings in shares of Gilead Sciences by 1,456.8% during the first quarter. OMERS ADMINISTRATION Corp now owns 1,163,062 shares of the biopharmaceutical company’s stock valued at $162,096,000 after purchasing an additional 1,088,354 shares during the last quarter. Finally, Van Diest Capital LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $286,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $129.31 on Monday. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock’s 50-day moving average price is $129.55 and its 200-day moving average price is $135.62. The stock has a market capitalization of $160.55 billion, a price-to-earnings ratio of 17.62 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the firm posted $1.81 EPS. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider owned 124,234 shares in the company, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 77,000 shares of company stock valued at $9,978,740 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

GILD has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a report on Monday, July 6th. The Goldman Sachs Group increased their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Citigroup raised their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Morgan Stanley cut their price objective on Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, July 8th. Finally, Rothschild & Co Redburn reduced their price objective on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $158.33.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.